Johnson & Johnson (NYSE:JNJ) Shares Sold by Schneider Downs Wealth Management Advisors LP

[view original post]

Schneider Downs Wealth Management Advisors LP reduced its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 6.9% in the 1st quarter, Holdings Channel.com reports. The fund owned 4,031 shares of the company’s stock after selling 298 shares during the quarter. Schneider Downs Wealth Management Advisors LP’s holdings in Johnson & Johnson were worth $714,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Family CFO Inc acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $34,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $38,000. Advocacy Wealth Management Services LLC boosted its holdings in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at about $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $174.20 on Friday. The firm’s 50 day simple moving average is $176.00 and its 200-day simple moving average is $174.37. The company has a market cap of $458.39 billion, a P/E ratio of 25.36, a price-to-earnings-growth ratio of 3.28 and a beta of 0.63. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.48 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 65.79%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. UBS Group decreased their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Raymond James lifted their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Citigroup cut their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Finally, SVB Leerink dropped their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $189.89.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.